Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769134 | 0.84 | GAA (0.55) | ALDH1A1SMN1; SMN2PPARGPPARA | |
| SCHEMBL5429541 | 0.81 | PLA2G4B (0.68) | PLA2G4BTSHRALDH1A1ALOX15PLA2G4A | |
| SCHEMBL1767709 | 0.80 | NQO1 (0.54) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL8744429 | 0.78 | PLA2G4B (0.73) | PLA2G4BTSHRPLA2G4A | |
| SCHEMBL4772404 | 0.78 | ALDH1A1 (0.47) | PLA2G4BTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4772112 | 0.78 | LMNA (0.47) | ALDH1A1SMN1; SMN2PPARGPPARA | |
| SCHEMBL9163844 | 0.77 | PLA2G4B (0.76) | PLA2G4BTSHRPLA2G4A | |
| SCHEMBL7369439 | 0.77 | PLA2G4B (0.76) | PLA2G4BTSHRPLA2G4A | |
| SCHEMBL15199296 | 0.77 | PLA2G4B (0.76) | PLA2G4BTSHRPLA2G4A | |
| SCHEMBL11842813 | 0.77 | PLA2G4B (0.76) | PLA2G4BTSHRPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | PLA2G4B 3053/4885TSHR 962/4885ALDH1A1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.